Suzuken (9987) Approves Share Buyback of Up to ¥18.0 billion (5.91% of Shares Outstanding) | TDnet Disclosure

Suzuken (9987) announced on August 28, 2026, through a regulatory filing that it has resolved to acquire treasury stock with a maximum acquisition amount of ¥18 billion, a maximum number of 4,000,000 shares, representing up to 5.91% of issued shares (excluding treasury stock). The company is a major pharmaceutical wholesale distributor, primarily engaged in the distribution and sales of prescription drugs, over-the-counter medicines, and medical devices. At this scale, a 5.91% reduction in share count would translate to approximately 6% accretion to earnings per share, assuming comparable profit levels. The acquisition period runs from September 1, 2026, through March 19, 2027, using ToSTNeT-3 (off-auction purchases). This method involves purchasing at the previous day's closing price before market open on the following business day and frequently serves as a counterparty for block sales from major shareholders.

The implied acquisition price is ¥4,500 per share, approximately 12% below the closing price of ¥5,089 on the announcement date, suggesting the company intends to purchase at lower price levels. The actual acquisition amount may fall short of the stated ceiling. The restriction to off-auction purchases points to a pre-arranged counterparty or a systematic acquisition framework already in place. Within the pharmaceutical distribution sector, self-buyback programs have become a standard mechanism for shareholder returns as industry consolidation accelerates.

The authorization enhances capital efficiency prospects for the company. The ¥18 billion outlay over nine months indicates a dialogue-based, phased acquisition strategy with the market. *Speculation: This scale of buyback suggests the company has financial flexibility relative to cash outflows and prioritizes shareholder value creation in its capital allocation decisions.